Contact Information: Contact: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com
Cleveland BioLabs Granted First Patent for Protectan CBLB502
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - July 8, 2008) - Cleveland BioLabs, Inc. (NASDAQ : CBLI )
announced today that its first patent for Protectan CBLB502 was granted by
the Eurasian Patent Organization (EAPO), which includes nine member
countries. This patent covers the method of protecting a mammal from
radiation using flagellin or its derivatives, including Protectan CBLB502.
Cleveland BioLabs has filed over twenty patent applications in the U.S. and
internationally, around various properties of Protectan CBLB502 and related
compounds, including methods of use and composition of matter. Yakov
Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, noted that
the EAPO patent was the first of several expected approvals. "We have been
progressing well with patent examination in various geographies and we hope
to receive the first of our U.S. patents related to method of use for
Protectan CBLB502 in the coming months."
Protectan CBLB502 is a derivative of a microbial protein that reduces
injury from acute stresses, such as radiation and chemotherapy, by
mobilizing several natural cell protecting mechanisms, including inhibition
of programmed cell death (apoptosis), reduction of oxidative damage and
induction of regeneration promoting cytokines.
Cleveland BioLabs received a contract from the Department of Defense valued
at up to $8.9 million for the advanced development of Protectan CBLB502 as
a medical radiation countermeasure to treat radiation injury following
exposure to radiation from nuclear or radiological weapons. Protectan
CBLB502 is undergoing expedited approval for this use through the FDA's
two-animal rule requiring efficacy in animals and safety testing in a
representative sample of healthy human volunteers. Protectan CBLB502 has
demonstrated efficacy in multiple animal species including non-human
primates and is expected to start human safety studies in 2008. A Phase
I/II medical trial for Protectan CBLB502 in head and neck cancer patients
for reduction of radiation and chemotherapy toxicities is also expected to
start later in 2008.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland
Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland
BioLabs, Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's periodic filings with the
Securities and Exchange Commission.